[go: up one dir, main page]

MX2012007340A - Anticuerpos anti/her3 y usos de los mismos. - Google Patents

Anticuerpos anti/her3 y usos de los mismos.

Info

Publication number
MX2012007340A
MX2012007340A MX2012007340A MX2012007340A MX2012007340A MX 2012007340 A MX2012007340 A MX 2012007340A MX 2012007340 A MX2012007340 A MX 2012007340A MX 2012007340 A MX2012007340 A MX 2012007340A MX 2012007340 A MX2012007340 A MX 2012007340A
Authority
MX
Mexico
Prior art keywords
her3 antibodies
antibodies
her3
production
methods
Prior art date
Application number
MX2012007340A
Other languages
English (en)
Inventor
Guy Georges
Nikolaos Dimoudis
Birgit Bossenmaier
Thomas Friess
Irene Kolm
Valeria Lifke
Ekkehard Moessner
Hans-Willi Krell
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42126432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012007340(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2012007340A publication Critical patent/MX2012007340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos ligantes de HER3 humano (anticuerpo anti-HER3), a método para su producción, a composiciones farmacéuticas que contienen dichos anticuerpos, y a usos de los mismos.
MX2012007340A 2009-12-22 2010-12-17 Anticuerpos anti/her3 y usos de los mismos. MX2012007340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015831 2009-12-22
PCT/EP2010/070062 WO2011076683A1 (en) 2009-12-22 2010-12-17 Anti-her3 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2012007340A true MX2012007340A (es) 2012-08-01

Family

ID=42126432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007340A MX2012007340A (es) 2009-12-22 2010-12-17 Anticuerpos anti/her3 y usos de los mismos.

Country Status (33)

Country Link
US (4) US8859737B2 (es)
EP (1) EP2516469B1 (es)
JP (2) JP5680671B2 (es)
KR (2) KR20120098911A (es)
CN (1) CN102822201B (es)
AR (1) AR079551A1 (es)
AU (1) AU2010335282B2 (es)
BR (1) BR112012015255A2 (es)
CA (1) CA2782571C (es)
CL (1) CL2012001649A1 (es)
CO (1) CO6551674A2 (es)
CR (1) CR20120284A (es)
CY (1) CY1117563T1 (es)
DK (1) DK2516469T3 (es)
EC (1) ECSP12011995A (es)
ES (1) ES2571226T3 (es)
HR (1) HRP20160737T1 (es)
HU (1) HUE029026T2 (es)
IL (1) IL220162A (es)
MA (1) MA33892B1 (es)
MX (1) MX2012007340A (es)
MY (1) MY161909A (es)
NZ (1) NZ600262A (es)
PE (1) PE20121616A1 (es)
PH (1) PH12012501157A1 (es)
PL (1) PL2516469T3 (es)
RS (1) RS54795B1 (es)
RU (1) RU2560583C2 (es)
SG (1) SG181894A1 (es)
SI (1) SI2516469T1 (es)
TW (1) TWI421092B (es)
UA (1) UA107821C2 (es)
WO (1) WO2011076683A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
JP5587975B2 (ja) * 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
CN102822201B (zh) * 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
US9884904B2 (en) 2010-03-10 2018-02-06 Hoffmann-La Roche Inc. Method for purifying polypeptide solutions
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
ITRM20100577A1 (it) * 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
MX2013009151A (es) 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
KR101517320B1 (ko) 2011-04-19 2015-05-28 메리맥 파마슈티컬즈, 인크. 단일특이적 및 이중특이적 항-igf-1r 및 항 erbb3 항체
MY171038A (en) 2011-08-23 2019-09-23 Roche Glycart Ag Bispecific antigen binding molecules
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
MX357391B (es) * 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
ES2745684T3 (es) 2011-11-23 2020-03-03 Medimmune Llc Moléculas de unión específicas para HER3 y usos de las mismas
KR20140098834A (ko) 2011-11-30 2014-08-08 제넨테크, 인크. 암에서의 erbb3 돌연변이
WO2013084147A2 (en) * 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
NZ702241A (en) 2012-08-07 2018-04-27 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
US9180185B2 (en) * 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
CN105209493B (zh) * 2013-03-14 2019-05-03 德克萨斯州大学系统董事会 用于诊断和治疗用途的her3特异性单克隆抗体
CN105246508A (zh) 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
CA2907776C (en) * 2013-04-16 2020-04-14 Genentech, Inc. Pertuzumab variants and evaluation thereof
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CN106255705B (zh) 2014-05-14 2021-01-08 豪夫迈·罗氏有限公司 结合HER3β-发夹和HER2域II的HER3/HER2双特异性抗体
EP3143048B1 (en) 2014-05-14 2019-08-28 F. Hoffmann-La Roche AG Anti-her3 antibodies binding to the beta-hairpin of her3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
EP3091033A1 (en) * 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
CA3011949A1 (en) 2016-03-15 2017-09-21 Merrimack Pharmaceuticals, Inc. Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
KR101923641B1 (ko) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 항her3 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
IL126303A (en) * 1996-03-27 2002-05-23 Genentech Inc ErbB3 ANTIBODIES
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
US7744882B2 (en) * 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
EP1283053A1 (en) * 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN100424175C (zh) 2002-03-26 2008-10-08 上海泽生科技开发有限公司 ErbB-3 用于肿瘤治疗的方法和组合物
NZ591970A (en) 2003-01-22 2012-11-30 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
AU2004261229A1 (en) 2003-07-29 2005-02-10 Eisai, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
EP1663306A2 (en) 2003-09-05 2006-06-07 Genentech, Inc. Antibodies with altered effector functions
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
US20090175854A1 (en) 2004-09-08 2009-07-09 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
JP5255435B2 (ja) 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
CA2605697A1 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
JP5373396B2 (ja) 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2518508A1 (en) 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
EP2138511A1 (en) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
UA104868C2 (uk) 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
EP2387711B1 (en) 2009-01-15 2015-04-22 Laboratory Corporation of America Holdings Methods of determining patient response by measurement of her-3
AU2010226453B2 (en) 2009-03-20 2013-11-21 Genentech, Inc. Bispecific anti-HER antibodies
JP5587975B2 (ja) 2009-04-07 2014-09-10 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
AU2010242914B2 (en) 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
SG178509A1 (en) 2009-08-21 2012-04-27 Merrimack Pharmaceuticals Inc Antibodies against the ectodomain of erbb3 and uses thereof
JP2013507378A (ja) 2009-10-09 2013-03-04 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
WO2011056124A1 (en) 2009-11-04 2011-05-12 Affibody Ab Her3 binding polypeptides
CN105999263B (zh) 2009-11-13 2021-06-29 第一三共欧洲有限公司 用于治疗或预防人表皮生长因子受体-3(her-3)相关疾病的材料和方法
CN102822201B (zh) * 2009-12-22 2014-09-24 罗切格利卡特公司 抗her3抗体及其用途
EP2544680B1 (en) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Use of erbb3 inhibitors in the treatment of triple negative breast cancer
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
WO2012019024A2 (en) 2010-08-04 2012-02-09 Immunogen, Inc. Her3-binding molecules and immunoconjugates thereof
AU2011286407A1 (en) 2010-08-06 2013-02-21 Amgen Use of HER3 binding agents in prostate treatment
BR112013004012B1 (pt) 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
JP2014504850A (ja) 2010-09-30 2014-02-27 メルク・シャープ・エンド・ドーム・コーポレイション 抗ｈｅｒ３抗体の製造、特徴づけ及びその用途
US9346889B2 (en) 2010-10-18 2016-05-24 Mediapharma S.R.L. ErbB3 binding antibody
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
MX348637B (es) 2010-11-01 2017-06-22 Symphogen As Anticuerpos y composiciones anti-her3.
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
MX357391B (es) 2011-09-30 2018-07-06 Regeneron Pharma Anticuerpos anti-erbb3 y usos de los mismos.

Also Published As

Publication number Publication date
CL2012001649A1 (es) 2012-10-12
WO2011076683A1 (en) 2011-06-30
HUE029026T2 (en) 2017-01-30
KR20140130751A (ko) 2014-11-11
JP2015109848A (ja) 2015-06-18
ECSP12011995A (es) 2012-07-31
US20170174784A1 (en) 2017-06-22
CN102822201A (zh) 2012-12-12
MY161909A (en) 2017-05-15
SG181894A1 (en) 2012-08-30
PH12012501157A1 (en) 2012-10-29
RU2012129735A (ru) 2014-01-27
IL220162A0 (en) 2012-07-31
HK1175183A1 (en) 2013-06-28
US20140377273A1 (en) 2014-12-25
EP2516469A1 (en) 2012-10-31
PE20121616A1 (es) 2012-12-05
PL2516469T3 (pl) 2017-08-31
MA33892B1 (fr) 2013-01-02
CA2782571C (en) 2018-01-23
US10196456B2 (en) 2019-02-05
JP5680671B2 (ja) 2015-03-04
EP2516469B1 (en) 2016-03-30
RS54795B1 (sr) 2016-10-31
RU2560583C2 (ru) 2015-08-20
KR20120098911A (ko) 2012-09-05
CR20120284A (es) 2012-09-04
HRP20160737T1 (hr) 2016-07-15
AU2010335282B2 (en) 2015-05-21
UA107821C2 (en) 2015-02-25
BR112012015255A2 (pt) 2017-01-10
AR079551A1 (es) 2012-02-01
TWI421092B (zh) 2014-01-01
CN102822201B (zh) 2014-09-24
CA2782571A1 (en) 2011-06-30
ES2571226T3 (es) 2016-05-24
NZ600262A (en) 2013-06-28
US9611331B2 (en) 2017-04-04
DK2516469T3 (en) 2016-05-02
US20110171222A1 (en) 2011-07-14
AU2010335282A1 (en) 2012-07-12
US8859737B2 (en) 2014-10-14
TW201130510A (en) 2011-09-16
JP2013514793A (ja) 2013-05-02
CO6551674A2 (es) 2012-10-31
IL220162A (en) 2017-04-30
CY1117563T1 (el) 2017-04-26
US20140377272A1 (en) 2014-12-25
SI2516469T1 (sl) 2016-05-31

Similar Documents

Publication Publication Date Title
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
WO2010145792A8 (en) Bispecific antigen binding proteins
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MY178926A (en) Bispecific anti-vegf/anti-ang-2 antibodies
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MY162791A (en) Anti-il-23 antibodies
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
TN2010000213A1 (en) Wise binding antibodies and epitopes
PH12015501420A1 (en) Human anti-tau antibodies
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MY166530A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamide
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MX340683B (es) Anticuerpos anti-vla-4.
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12015500751A1 (en) Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
WO2010136483A3 (en) Antigen-binding proteins
GB201303865D0 (en) Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.

Legal Events

Date Code Title Description
FG Grant or registration